2022 Round Table Sessions

Initiated in 2015, the Round Table Discussions are a core feature of the CGC Annual Meeting. This format allows attendees to gather in a small group to discuss current practices in clinical genomics, emerging technologies, and critical concepts that affect clinical laboratory operations.
On Tuesday, August 2, CGC 2022 will feature these small breakout sessions for both in-person and virtual attendees. As you register for the meeting, please select your desired topic. Virtual participants will move into different chat rooms for topic-specific gatherings. There is a limit of 12 people for each in-person topic and 16 people for each virtual topic, so please register SOON.


2022 Round Table Session include the following topics from which participants may choose during registration:

  1. Practical Approaches to Enhanced Accessibility of Molecular Diagnostics in Community and Low Resource Settings

  2. Opportunities and Challenges in Adoption of New Technologies in Molecular Diagnostics

  3. Harmonizing Data Sharing for Omics in Adult and Pediatric Tumors

  4. Validation and Implementation of Testing for Cancer Predisposition Syndromes in Hematologic and Solid Tumors

  5. Best Practices for Genomic-guided Immunotherapy for Cancer

  6. Best Practices and Clinical Utility for Circulating Tumor DNA Testing

  7. Applications of Advanced Genomic Technologies in Constitutional Testing

  8. Detection of Gene Rearrangements by Next Generation Sequencing (NGS) and Optical Genome Mapping

  9. Automation of Complex Genomic Variant Reporting from NGS and Microarray Technologies

  10. Pre-analytical Determinants in Molecular Diagnostics

  11. Clinical Utility of MRD Monitoring for Leukemia 

  12. Best Practices and Clinical Utility of Genomic Testing for Somatic Overgrowth and Vascular Anomalies

  13. Clinical Implementation of Pharmacogenomics

  14. Clinical Implementation of Whole Genome Sequencing

  15. Best Practices in the Classification and Testing of Multiple Myeloma

  16. Molecular vs. Technology-based Classification of Hematologic Malignancies